Medscape September 9, 2024
(Reuters) -Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining drugmakers vying for a share of the lucrative obesity treatment market and sending its shares up 20% on Monday.
The experimental drug is part of the second generation of weight-loss pills under development by companies including Pfizer and Roche, which aims to offer a more convenient alternative to injections.
Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also developing oral weight-loss treatments.
“We’re very pleased with the totality of the data… seeing in particular, no red flags,” Mizuho analyst Graig Suvannavejh said in a note.
Shares of Terns...
Today's Sponsors
Today's Sponsor